Dabrefenib-Trametinib combination shows durable RFS benefit in BRAF v600-mutant melanoma

Source: Healio, December 2018

Adjuvant treatment with dabrafenib plus trametinib demonstrated a durable RFS benefit compared with placebo for patients with resected stage III BRAF V600-mutant melanoma, according to long-term follow-up from a randomized phase 3 trial.

“Patients with high-risk resectable melanoma represent a broad and diverse group; therefore, there is great clinical interest in understanding outcomes according to baseline characteristics,” Axel Hauschild, MD, PhD, professor and head of Interdisciplinary Skin Cancer Center in the department of dermatology at University Hospital Schleswig-Holstein in Kiel, Germany, and colleagues wrote. “Subgroup analysis of RFS in this study demonstrated that the RFS benefit observed with dabrafenib plus trametinib versus placebo was similar regardless of baseline disease stage, metastatic load or tumor ulceration status.”

The double-blind, placebo-controlled COMBI-AD trial included 870 adults who underwent complete surgical resection of stage IIIA, IIIB or IIIC BRAF V600E or V600K mutant melanoma.